Get all your news in one place.
100's of premium titles.
One app.
Start reading
StockNews.com
StockNews.com
Business
Riddhima Chakraborty

1 Pharma Stock to Buy for Under $1 This December

Rigel Pharmaceuticals (RIGL) surpassed EPS estimates by 18.5% for its 2022 third quarter. Moreover, the U.S. Food and Drug Administration approved its REZLIDHIA (olutasidenib) capsules for treating adult patients with relapsed or refractory (R/R) acute myeloid leukemia. REZLIDHIA is expected to be incredibly beneficial for patients with poor prognoses and is a solid addition to RIGL’s product portfolio.

RIGL shares soared on the news. They have gained 30.2% over the past month. However, RIGL has lost 67.1% year-to-date and 64.9% over the past year to close the last trading session at $0.87.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.